BCRX - Company ID 0000882796
The table below shows BIOCRYST PHARMACEUTICALS INC's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $96.97M | $154.97M | $171.59M | $84.08M | $88.03M | $105.19M |
| Short-term investments | $278.03M | $197.60M | $66.81M | $128.79M | $172.00M | $189.90M |
| Receivables | $121.79M | $110.76M | $109.27M | $91.33M | $91.18M | $93.39M |
| Inventory | $13.74M | $6.06M | $5.99M | $5.23M | $5.04M | $6.87M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $531.15M |
| $484.68M |
| $373.63M |
| $355.68M |
| $398.46M |
| $409.98M |
| Property, plant & equipment | $1.66M | $9.06M | $9.37M | $8.40M | $8.46M | $7.59M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $591.07M | $557.85M | $465.05M | $446.42M | $457.19M | $480.05M |
| Accounts payable | $14.58M | $11.46M | $10.96M | $5.57M | $8.59M | $10.05M |
| Total current liabilities | $195.83M | $208.85M | $195.39M | $190.24M | $177.16M | $139.85M |
| Long-term debt | $395.61M | $395.40M | $395.20M | $194.37M | $242.79M | $315.41M |
| Total liabilities | $988.45M | $1.01B | $1.02B | $834.31M | $878.78M | $931.97M |
| Retained earnings | -$2.11B | -$2.15B | -$2.23B | -$1.75B | -$1.76B | -$1.77B |
| Total equity | -$397.38M | -$454.29M | -$553.84M | -$387.89M | -$421.59M | -$451.93M |